Vir Biotechnology (VIR) is a commercial-stage immunology firm focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.
Vir assembled four technology platforms that stimulate and enhance the immune system by exploiting critical observations of natural immune processes.
Vir’s current pipeline consists of product candidates targeting COVID-19, hepatitis B and hepatitis D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.
Annual General 2022 Meeting and Voting
Vir Biotechnology reminds stockholders that it will hold its 2022 Annual General Meeting of Stockholders on Friday, May 20, 2022, at 11:30 a.m. PT.
The Annual Meeting will be held in virtual format only via live audio webcast.
- Instructions on how to connect to the Annual Meeting and participate via the Internet can be found at www.virtualshareholdermeeting.com/VIR2022.
- Online access to the Annual Meeting will begin at 11:15 a.m. PT. Stockholders should allow ample time for the check-in procedures.
Vir Biotechnology’s stockholders of record as of March 28, 2022 (the “Record Date”) can attend and vote at the Annual Meeting by accessing the meeting center at www.virtualshareholdermeeting.com/VIR2022 and entering the control number on the proxy card or Notice of Internet Availability of Proxy Materials previously received.
Whether or not stockholders plan to virtually attend the Annual Meeting, Vir Biotechnology urges them to vote and submit their proxy in advance of the Annual Meeting by one of the methods described in the proxy materials for the Annual Meeting.
Click here to read more about Vir Biotechnology.